PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
5.61%
Revenue growth 1.25-1.5x 3141.T's 4.43%. Bruce Berkowitz would check if differentiation or pricing power justifies outperformance.
7.07%
Gross profit growth at 50-75% of 3141.T's 11.22%. Martin Whitman would question if cost structure or brand is lagging.
23.00%
EBIT growth 50-75% of 3141.T's 32.48%. Martin Whitman would suspect suboptimal resource allocation.
18.46%
Operating income growth under 50% of 3141.T's 101.29%. Michael Burry would be concerned about deeper cost or sales issues.
42.27%
Net income growth 1.25-1.5x 3141.T's 34.16%. Bruce Berkowitz would see if strategic cost cutting or product mix explains this difference.
42.25%
EPS growth 1.25-1.5x 3141.T's 34.13%. Bruce Berkowitz would check if strategic initiatives like cost cutting or better capital management explain the difference.
42.25%
Diluted EPS growth 1.25-1.5x 3141.T's 34.13%. Bruce Berkowitz would verify if strategic moves (e.g., targeted acquisitions, cost cuts) explain the edge.
-0.00%
Share reduction while 3141.T is at 0.04%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
-0.00%
Reduced diluted shares while 3141.T is at 0.00%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
22.22%
Dividend growth of 22.22% while 3141.T is flat. Bruce Berkowitz would see if this can become a bigger advantage long term.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
65.40%
10Y revenue/share CAGR under 50% of 3141.T's 134.77%. Michael Burry would suspect a lasting competitive disadvantage.
61.06%
5Y revenue/share CAGR similar to 3141.T's 65.48%. Walter Schloss might see both companies benefiting from the same mid-term trends.
34.47%
3Y revenue/share CAGR similar to 3141.T's 31.72%. Walter Schloss would assume both companies experience comparable short-term cycles.
-100.00%
Both show negative 10Y OCF/share CAGR. Martin Whitman would question if the entire market or product set is shrinking or too capital-intensive.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
155.91%
Below 50% of 3141.T's 315.77%. Michael Burry would worry about a sizable gap in long-term profitability gains vs. the competitor.
137.88%
5Y net income/share CAGR above 1.5x 3141.T's 44.63%. David Dodd would confirm if the firm’s strategy is more effective in generating mid-term profits.
84.91%
3Y net income/share CAGR above 1.5x 3141.T's 43.93%. David Dodd would confirm the company’s short-term strategies outmatch the competitor significantly.
215.84%
10Y equity/share CAGR at 75-90% of 3141.T's 241.47%. Bill Ackman would push for either higher ROE or more earnings retention to catch the competitor.
132.15%
5Y equity/share CAGR above 1.5x 3141.T's 58.41%. David Dodd might see stronger earnings retention or fewer asset impairments fueling growth.
65.78%
3Y equity/share CAGR above 1.5x 3141.T's 37.62%. David Dodd verifies the company’s short-term capital management far exceeds the competitor’s pace.
-8.33%
Cut dividends over 10 years while 3141.T stands at 16127.75%. Joel Greenblatt suspects a weaker ability to return capital vs. the competitor.
-8.33%
Negative 5Y dividend/share CAGR while 3141.T stands at 158.46%. Joel Greenblatt sees a weaker commitment to dividends vs. a competitor that might be growing them.
57.14%
3Y dividend/share CAGR at 50-75% of 3141.T's 90.91%. Martin Whitman might see a weaker short-term approach to distributing cash.
34.92%
Our AR growth while 3141.T is cutting. John Neff questions if the competitor outperforms in collections or if we’re pushing credit to maintain sales.
1.59%
We show growth while 3141.T is shrinking stock. John Neff wonders if the competitor is more disciplined or has weaker demand expectations.
5.03%
Asset growth above 1.5x 3141.T's 1.95%. David Dodd checks if M&A or new capacity expansions are value-accretive vs. competitor's approach.
4.95%
BV/share growth above 1.5x 3141.T's 3.07%. David Dodd confirms if consistent profit retention or fewer write-downs yield faster equity creation.
-10.52%
We’re deleveraging while 3141.T stands at 0.98%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
No Data
No Data available this quarter, please select a different quarter.
-45.14%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.